A picture is emerging of how HIV subverts a normal immunological surveillance mechanism to establish primary infection. This involves the infection of dendritic cells at mucosal surfaces: as these cells then mature, they transport the virus to lymphoid tissue, where viral replication begins and infection of CD4 + T cells occurs.
The disturbing figures released by the United Nations Programme on AIDS at the end of last year revealed that more than 33 million people worldwide are now infected with human immunodeficiency virus (HIV). The vast majority of HIV transmissions take place across a mucous membrane, yet the very earliest events of HIV infectiondespite their obvious importance for preventative and therapeutic strategies -remain obscure. Recent work from a number of groups, however, has demonstrated how a key immunological surveillance mechanism can be subverted by HIV, allowing the virus to gain access to its main target cell population, the CD4 + T cell. The dendritic cell is the central component in this process.
Dendritic cells are now understood to provide a highly specialised mechanism whereby an antigen encountered in peripheral tissues, notably skin and mucosal membranes, can be brought together with the T cells that will constitute the immune response against it. It has been pointed out that the immune system needs to have some way of coordinating a successful T-cell response in the face of problems posed by the scarcity of T cells with an appropriate antigenic specificity amongst the abundance of available lymphocytes, and the relatively low avidity of any interaction between antigen and a low-affinity T-cell receptor expressed by a quiescent cell lacking the critical costimulatory molecules required to trigger a full T-cell response [1] . The problem is more than just finding a needle in a haystack: here, the needle is not only hard to find, it is also blunt. Dendritic cells deal with this situation in a remarkable way, and the key to understanding their role has been the appreciation that the functions of these cells change as they mature [2] .
The principal form of dendritic cell in the tissues, exemplified by Langerhans cells in epithelial and mucosal surfaces, is specialised for antigen capture. These cells, also referred to as immature or 'processing' dendritic cells, have developed and refined the ability to acquire foreign proteins by phagocytosis or pinocytosis and reduce them to an array of antigens ready for presentation on the cell surface [2] . These immature cells express chemokine receptors, principally CCR5 and CCR6, which act to alert and direct the cells to a site of inflammation where the chemokine ligands MIP-1α, MIP-1β, RANTES and MIP-3α are being produced [3] . Once loaded with antigen, the dendritic cells then take the back route to the lymph node via the draining lymphatic system. As the cells travel, they also mature and alter their profile of cellsurface molecules, so the dendritic cells that arrive in the lymph node now express a range of costimulatory molecules designed to attract and trigger the appropriate T cells to respond to the antigen load that they are presenting. The principal chemokine receptor expressed by mature or 'presenting' dendritic cells is CCR7, the ligand for which, MIP-3β, is produced in the T-cell-rich areas of lymphoid tissue, thus drawing the dendritic cells towards the T cells [3] . One of the central interactions that now takes place is between the CD40 ligand (CD40L) expressed on the surface of T cells and CD40 on mature dendritic cells: this appears to be critical for the survival, maturation and cytokine production of the dendritic cells, whilst at the same time facilitating the antigen-specific priming of the T cells [4] .
Mature dendritic cells are believed to be the most potent stimulators of CD4 + helper T lymphocyte and CD8 + cytotoxic T lymphocyte (CTL) responses in the immune system [5] . Recent studies have shown that a dendritic cell activated by CD40 triggering can serve to bridge the gap between the help supplied by responding CD4 + T cells and that needed to stimulate specific CTLs, without necessarily requiring all the players to be in the same place at the same time [6] . The authors speculate that the direct infection of dendritic cells could directly empower them to stimulate CTLs and bypass the need for CD4 + help: a prediction from this model is that the ability of a pathogen to infect and activate dendritic cells would correlate with the independence of specific CTLs from CD4 + T-cell help [6] .
How has HIV taken advantage of this highly sophisticated system to establish a persistent infection of CD4 + T cells? Increasingly, a consensus has emerged that dendritic cells are likely to be the first cells targeted by HIV in the mucosa [7] . But although the early controversy of whether dendritic cells were directly infected with HIV or simply carrying the virus on their surface has largely been resolved in favour of the former [7] , the role of dendritic cells in disseminating the virus to T cells has not been clear. A recent paper by Granelli-Piperno and colleagues [8] puts some missing pieces into the picture that is emerging from a number of studies. This group had previously shown that HIV could enter immature dendritic cells but that replication was incomplete, with only very early HIV transcripts being produced [9] . In the presence of T cells, however, the virus in mature dendritic cells is triggered to set up a vigorous and productive infection which is rapidly transmitted to the T cells.
By using artificial constructs of HIV that can readily enter cells but are unable to carry out further replication, the authors show that only the first round of HIV replication takes place in the dendritic cells and that all the subsequent viral replication occurs in the T cells [8] . Earlier suggestions that the CD40-CD40L interaction plays a crucial part in triggering replication [7] were confirmed by incubating purified mature dendritic cells with CD40L-transfected fibroblasts: this stimulated HIV replication in the dendritic cells [8] . It now looks as though HIV gains access to the lymphoid system by infecting the dendritic cells that guard mucosal and epithelial surfaces, and then hitching a ride to the nearest lymphoid tissue in a state of arrested replication. The increase in mucosal dendritic cell numbers at sites of inflammation probably contributes to the increased risk of HIV transmission in the presence of genital infections. Upon reaching the lymphoid regions, the now mature dendritic cells attract and are attracted by CD4 + T cells, which, in the course of their normal positive feedback interaction with the dendritic cells through their costimulatory molecules, can release the block to the virus life cycle and allow new HIV particles to be rapidly made (Figure 1 ). The emerging virions now have access to a wealth of activated T cells in the vicinity, so can leave the shelter of the dendritic cells for a more permissive host.
A number of questions still remain. It seems likely that the use of dendritic cells for initial HIV entry imposes the selection for viral strains that use the CCR5 receptor expressed on immature dendritic cells in order to establish primary infection. But although immature dendritic cells may still express a certain amount of CXCR4, there seems to be a barrier to the entry of the later, more aggressive viral strains that use this receptor, and this has yet to be fully explained. The mechanism by which virus replication is arrested until the first contact is established between T cells and dendritic cells is not at all understood. The fate of the carrier dendritic cells once they have handed on their passengers to the T cells is also not clear. There is some suggestion that these dendritic cells may die through apoptosis or following recognition by CTLs [5] , but it is also plausible that many survive and continue their mission to stimulate HIV-specific responses.
Is the function of the carrier dendritic cells compromised by HIV infection? Studies on dendritic cells derived from the blood of patients at later stages of HIV infection suggest that there is a generalised defect in antigenpresenting function, which may underlie the ultimate Dispatch R249 failure of the immune response to control the virus [5] . Primary infection with HIV often provokes an early and vigorous CTL response, however, in which the infected dendritic cells are very probably playing a part. Indeed, the proposed ability of infected dendritic cells to bypass the requirement for CD4 + T-cell help [6] could explain how such a strong CTL response can be initiated and maintained for so long in the apparent absence of HIV-specific helper responses in most infected people. Increasing evidence suggests, however, that CTLs are functionally deficient without the support of CD4 + T-cell help [10] . The implications of early dendritic cell infection for the successful generation of HIV-specific immunity therefore need to be unravelled.
Are there stages in the passage of HIV from mucosa to lymph node that provide targets for therapeutic intervention? The apparent requirement for HIV to use CCR5 to establish primary infection has already led to considerable efforts to identify agents that will block this receptor.
Once the dendritic cells have been infected, it is possible that drugs such as steroids may prevent their maturation and migration to the lymph nodes [8] . The recent study by Granelli-Piperno and colleagues [8] also suggests that strategies to disrupt the CD40-CD40L interaction could be potentially useful. Finally, the reported resistance of the virus sequestered in dendritic cells to the activity of the anti-HIV drug azidothymidine (AZT) [8] raises the question of how the spread of HIV infection could be controlled by therapy after the initial exposure: perhaps dendritic cells do become infected but are prevented from passing on the virus to T cells. These cells could still stimulate an effective immune response. HIV-specific cellular immune responses can be demonstrated in a surprising number of people with HIV exposure who remain seronegative [11] : this may reflect a low-level infection confined to a few dendritic cells that are still able to trigger CTLs and CD4 + responses.
Despite the questions that remain, it is clear that improving our understanding of how HIV breaks into the body by subverting some of our best defence mechanisms must give us a better opportunity to turn the tables in our favour in the future.
